The Food and Drug Administration gave DARA BioSciences (Nasdaq: DARA) some good news this week, providing the firm with “fast track” status for its proposed cancer pain relief treatment.
DARA is working with the National Cancer Institute on its proposed compound that would counter neuropathic pain that results from chemotherapy.
WRAL Tech Wire content partner MedCity News has the details. Read here.
Get the latest news alerts: Follow LTW at Twitter.
